EGFR and non-small cell lung carcinoma: A part of NSCLC patients demonstrates activating epidermal growth factor receptor gene (EGFR) mutations who represent effectiveness and well tolerance of EGFRspecific tyrosine kinase inhibitors (TKIs) therapy.